Results 71 to 80 of about 2,047,983 (266)

Social Support, Quality of Life, and Financial Toxicity Among Patients with Hepatocellular Carcinoma

Journal of Hepatocellular Carcinoma
Shuyue Liu,1– 3,* Yawen Xie,1– 3,* Tiantian Li,1– 3,* Yanxia Huang,1– 3 Danting Xu,1– 3 Linli Cai,1– 3 Yizhen Fu,1– 3 Jinbin Chen,1– 3 Yaojun Zhang,1– 3 Jia Huang,4 Zili Hu1– 3 1Department of Liver Surgery, Sun Yat-Sen University ...
Liu S, Xie Y, Li T, Huang Y, Xu D, Cai L, Fu Y, Chen J, Zhang Y, Huang J, Hu Z   +10 more
doaj  

Liver transplantation [PDF]

Current Opinion in Gastroenterology, 2005
Liver transplantation continues to change as we further define appropriate criteria for allocation and utilization of this scarce resource. The following review highlights new trends and ideas in this evolving field.Although the model for end-stage renal disease (MELD) scoring system appears to fairly accurately predict mortality while waiting for ...
openaire   +2 more sources

Tumor and germline testing with next generation sequencing in epithelial ovarian cancer: a prospective paired comparison using an 18‐gene panel

Molecular Oncology, EarlyView.
Genetic testing in epithelial ovarian cancer includes both germline and tumor‐testing. This approach often duplicates resources. The current prospective study assessed the feasibility of tumor‐first multigene testing by comparing tumor tissue with germline testing of peripheral blood using an 18‐gene NGS panel in 106 patients.
Elisabeth Spenard, Cristina Mitric, Melanie Care, Tracy L. Stockley, Raymond H. Kim, Jeanna McCuaig, Blaise Clarke, Laura Ranich, Clare Sheen, Sarah E. Ferguson, Liat Hogen, Taymaa May, Marcus Q. Bernardini   +12 more
wiley   +1 more source

Liquid biopsy epigenetics: establishing a molecular profile based on cell‐free DNA

Molecular Oncology, EarlyView.
Cell‐free DNA (cfDNA) fragments in plasma from cancer patients carry epigenetic signatures reflecting their cells of origin. These epigenetic features include DNA methylation, nucleosome modifications, and variations in fragmentation. This review describes the biological properties of each feature and explores optimal strategies for harnessing cfDNA ...
Christoffer Trier Maansson, Anders Lade Nielsen, Boe Sandahl Sorensen   +2 more
wiley   +1 more source

Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting

Molecular Oncology, EarlyView.
CARtein is a modular CAR platform that uses split inteins to splice antigen‐recognition modules onto a universal signaling backbone, enabling precise, scarless assembly without re‐engineering signaling domains. Deployed here against CD19 and CD20 in B‐cell malignancies, the design supports flexible multi‐antigen targeting to boost T‐cell activation and
Pablo Gonzalez‐Garcia, Noelia Moares, Wenjie Yi‐He, Rosa Luna‐Espejo, Ricardo Fernandez‐Cisnal, Javier Ocaña‐Cuesta, Juan P. Muñoz‐Miranda, Antonio Gabucio, Cecilia M. Fernandez‐Ponce, Francisco Garcia‐Cozar   +9 more
wiley   +1 more source

Adjuvant TACE Improves Prognosis After Resection in Dual-Phenotype Hepatocellular Carcinoma: A Propensity Score-Matched Study

Journal of Hepatocellular Carcinoma
Zijian Leng,1,* Taifeng Zhu,1,* Ziyue Huang,1,* Xiaokun Chen,1,* Yuce Lu,1 Yuehao Zhang,2 Xueshuai Wan,1 Xiaobo Yang,1 Lei Zhang,1 Haitao Zhao,1 Shunda Du,1 Zhonghai Zhao,3 Yongchang Zheng1 1Department of Liver Surgery ...
Leng Z, Zhu T, Huang Z, Chen X, Lu Y, Zhang Y, Wan X, Yang X, Zhang L, Zhao H, Du S, Zhao Z, Zheng Y   +12 more
doaj  

The prognostic value of microvascular invasion in early-intermediate stage hepatocelluar carcinoma: a propensity score matching analysis

BMC Cancer, 2018
Background Microvascular invasion (MVI) is well established as a negative prognostic factor for hepatocelluar carcinoma (HCC). However, its prognostic value in different subgroups of Barcelona Clinical Liver Cancer (BCLC) stages remains to be elucidated.
Junyi Shen, Jun Wen, Chuan Li, Tianfu Wen, Lvnan Yan, Bo Li, Jiayin Yang, Changli Lu   +7 more
doaj   +1 more source

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

Molecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz, Anna L. Bartkowiak, Michael Rose, Nora Kolks, Patrick Petzsch, Vandana Solanki, Anne Stoffel, Bianca Faßbender, Leandra Lepping, Julka Volkamer, Karl Köhrer, Marc Seifert, Tokameh Mahmoudi, Tahlita C. M. Zuiverloon, Günter Niegisch, Michèle J. Hoffmann   +15 more
wiley   +1 more source

Liver [PDF]

Laboratory Investigation, 2017
openaire   +5 more sources

A Multicenter Retrospective Study: Impact of First-Line Treatment Strategies on second-Line Efficacy and Safety of Regorafenib with or Without PD-1 Inhibitors in Unresectable Hepatocellular Carcinoma

Journal of Hepatocellular Carcinoma
Weihong Ma,1,2,* Yinyin Li,1,* Yinying Lu,1,2 Zhipeng Liang,3 Hongli Yu,1,2 Jie Han,1,2 Jiaqi Liu,1,2 Wenjing Wang,1,2 Caiyun Peng,1 Jiamin Cheng1 1Senior Department of Hepatology, The 5th Medical Center of the PLA General Hospital ...
Ma W, Li Y, Lu Y, Liang Z, Yu H, Han J, Liu J, Wang W, Peng C, Cheng J   +9 more
doaj